1. Home
  2. PRHI vs PHGE Comparison

PRHI vs PHGE Comparison

Compare PRHI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Presurance Holdings Inc.

PRHI

Presurance Holdings Inc.

N/A

Current Price

$0.59

Market Cap

9.1M

Sector

Finance

ML Signal

N/A

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$4.99

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRHI
PHGE
Founded
2009
2015
Country
United States
United States
Employees
N/A
57
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
9.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRHI
PHGE
Price
$0.59
$4.99
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
50.9K
64.4K
Earning Date
03-09-2026
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.25
52 Week High
$2.83
$8.50

Technical Indicators

Market Signals
Indicator
PRHI
PHGE
Relative Strength Index (RSI) 38.81 45.74
Support Level $0.53 $0.53
Resistance Level $0.87 $6.28
Average True Range (ATR) 0.06 1.05
MACD -0.02 -0.20
Stochastic Oscillator 6.07 24.32

Price Performance

Historical Comparison
PRHI
PHGE

About PRHI Presurance Holdings Inc.

Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: